Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, …

… Nirula had full access to all of the data in the study and take responsibility for the integrity of
the data and the accuracy of the data analysis. Drs Gottlieb and Nirula … Drs Nirula and Adams…

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-…

Background Early clinical studies suggested that the anti–interleukin-17 receptor A monoclonal
antibody brodalumab has efficacy in the treatment of psoriasis. Methods In two phase 3 …

Background Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate
the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. Stimulation of …

Baricitinib is an oral Janus kinase ( JAK )1/ JAK 2 inhibitor approved for the treatment of
rheumatoid arthritis ( RA ) that was independently predicted, using artificial intelligence ( AI ) …

Importance Preventive interventions are needed to protect residents and staff of skilled
nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. …

Background We assessed the efficacy and safety of brodalumab, a human monoclonal
antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, …

… Nirula, Ajay a ; Glaser, Scott M a ; Kalled, Susan L b ; Taylora, Frederick R b …
Correspondence to Ajay Nirula, Biogen Idec, 5200 Research Place, San Diego, CA 92130, USA …

Background Physicians treating patients with coronavirus disease 2019 (COVID-19) increasingly
believe that the hyperinflammatory acute stage of COVID-19 results in a cytokine storm. …